Katsumichi Fujimaki

Katsumichi Fujimaki

Auto-generated profile, based on publicly available information

Katsumichi Fujimaki

Department of Hematology, Fujisawa City Hospital, Fujisawa, Japan

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2024 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
TMTakuya Miyazaki
Takuya Miyazaki
TTTakayoshi Tachibana
Takayoshi Tachibana
TSTaisei Suzuki
Taisei Suzuki
AIAkihiko Izumi
Akihiko Izumi
KFKatsumichi Fujimaki
Katsumichi Fujimaki
HNHideaki Nakajima
Hideaki Nakajima
There are no clear criteria for selecting elderly patients with hematological malignancies eligible for allogeneic hematopoietic stem cell transplantation. This study aimed to evaluate inflammatory and nutritional status biomarkers as prognostic indicators of allogeneic transplantation in elderly patients. We compared the prognostic effects of four representative pretransplant biomarkers: C-reactive protein-to-albumin ratio (CAR), Glasgow prognostic score (GPS), prognostic nutritional index (PNI), and albumin-to-globulin ratio (AGR). In total, 143 patients aged ≥ 60 years who underwent their first allogeneic transplantation for hematological malignancies were enrolled between 2010 and 2020 in our single-center cohort. The median patient age was 65 (range, 60-72) years. Pretransplant high CAR, high GPS, and low PNI scores were associated with poor overall survival (OS), whereas AGR was not associated with OS. CAR stratified the OS most significantly among the four biomarkers (p < 0.001). Multivariate analyses revealed that only high CAR was an independent prognostic factor associated with OS (hazard ratio [HR], 1.98; p = 0.031) and that hematopoietic cell transplant-specific comorbidity index (HCT-CI) score ≥ 3 was also associated with OS (HR, 2.04; p = 0.012). High CAR was correlated with poor performance status, male sex, and high disease risk index scores, but not with high HCT-CI scores. When the patients were stratified into three groups according to a composite risk assessment using CAR and HCT-CI, the 3-year OS significantly decreased with increasing scores (82.8%, 50.3%, and 27.0%, respectively; p < 0.0001). CAR is the most useful prognostic indicator among the inflammatory and nutritional status biomarkers for allogeneic transplantation in elderly patients. Inflammatory and nutritional status in the elderly may be important prognostic factors for allogeneic transplantation, independent of HCT-CI scores.

1 June 2020 in Cancers
Verified
Journal Article
Open access
PDF file
ATAkihiro Takeshita
Akihiro Takeshita
NANorio Asou
Norio Asou
YAYoshiko Atsuta
Yoshiko Atsuta
HFHiroaki Furumaki
Hiroaki Furumaki
TSToru Sakura
Toru Sakura
TGthe Japan Adult Leukemia Study Group
the Japan Adult Leukemia Study Group
Background: After long-term analysis of the JALSG-APL204 study we recently reported that maintenance therapy with tamibarotene was more effective than all-trans retinoic acid (ATRA) by reducing relapse in APL patients. Here, the clinical significance of other important prognostic factors was evaluated with multivariate analyses. Patients and Methods: Newly diagnosed acute promyelocytic leukemia (APL) patients were registered with the study. Induction was composed of ATRA and chemotherapy. Patients who achieved molecular remission after consolidation were randomly assigned to maintenance with tamibarotene or ATRA. Results: Of the 344 eligible patients, 319 (93%) achieved complete remission (CR). After completing consolidation, 269 patients underwent maintenance random assignment—135 to ATRA, and 134 to tamibarotene. By multivariate analysis, overexpression of CD56 in blast was an independent unfavorable prognostic factor for relapse-free survival (RFS) (p = 0.006) together with more than 10.0 × 109/L WBC counts (p = 0.001) and the ATRA arm in maintenance (p = 0.028). Of all phenotypes, CD56 was related most clearly to an unfavorable prognosis. The CR rate, mortality rate during induction and overall survival of CD56+ APL were not significantly different compared with CD56− APL. CD56 is continuously an independent unfavorable prognostic factor for RFS in APL patients treated with ATRA and chemotherapy followed by ATRA or tamibarotene maintenance therapy.


3 January 2016 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
KFKatsumichi Fujimaki
Katsumichi Fujimaki
KMKazuho Miyashita
Kazuho Miyashita
RKRika Kawasaki
Rika Kawasaki
NTNaoto Tomita
Naoto Tomita

29 November 2017 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
KFKatsumichi Fujimaki
Katsumichi Fujimaki
YHYukako Hattori
Yukako Hattori
HNHideaki Nakajima
Hideaki Nakajima

1 January 2021 in BLOOD CELL THERAPY / The official journal of APBMT
Verified
Journal Article
Closed access
KFKatsumichi Fujimaki
Katsumichi Fujimaki
YHYuto Hibino
Yuto Hibino
KKKumiko Kishimoto
Kumiko Kishimoto
SWShinichiro Watanabe
Shinichiro Watanabe
SKSatoshi Koyama
Satoshi Koyama
HNHideaki Nakajima
Hideaki Nakajima
The prognosis for relapsed adult T-cell leukemia/lymphoma (ATL) after allogeneic hematopoietic stem cell transplantation is poor. Here, we report the case of a 67-year-old man who survived for 26 months after treatment with lenalidomide for post-transplant relapsed ATL. He underwent induction therapy with two cycles of modified VCAP-AMP-VECP and achieved complete remission. He received cord blood cell transplantation following a reduced-intensity conditioning regimen. Seven months after transplantation, swelling of the systemic lymph nodes appeared, and relapsed ATL was diagnosed based on a biopsy of the cervical lymph node. Treatment with 10 mg of lenalidomide induced partial remission. At 18 months after transplantation, skin tumors were successfully treated by increasing the dose of lenalidomide to 15 mg with the emergence of skin graft-versus-host disease. Although he died from ATL at 34 months after transplantation, systemic relapsed lesions were controlled by treatment with lenalidomide for 26 months. Our case suggests that lenalidomide is well tolerated and is an effective option for the treatment of post-transplant relapsed ATL.